Biotech and healthcare investors hope for rebound following weak 2021

Targeting long-term structural changes

clock • 5 min read
Biotech funding 'off the charts'
Image:

Biotech funding 'off the charts'

2021 was a difficult year for biotech equities, with the Nasdaq Biotechnology Index giving a full year performance of -0.6% and a total return of 0%, underperforming the S&P 500 benchmark by more than 25 percentage points. It was one of the worst years for the index.

As of 20 January, the Nasdaq Health Care Index was down 23.9% compared to 12 months prior. The industry experienced a lot of volatility throughout last year. Funds such as the L&G Healthcare Breakthrough...

To continue reading this article...

Join Investment week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Vince Childers of Cohen & Steers

Impact of Russia-Ukraine war ripples across real assets

Commodities and real estate affected

Vince Childers
clock 26 May 2022 • 4 min read
John Redwood, chief global strategist for Charles Stanley

Charles Stanley's Redwood: Chimerica is so last decade

Both have hit problems in 2022

John Redwood
clock 25 May 2022 • 6 min read
Industry Voice: UK is a rich seam to mine … and not just in commodities

Industry Voice: UK is a rich seam to mine … and not just in commodities

Richard Colwell, Head of UK Equities at Columbia Threadneedle Investments
clock 24 May 2022 • 11 min read
Trustpilot